Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(14%)
Results Posted
100%(2 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_2
4
57%
Ph not_applicable
2
29%
Ph phase_3
1
14%

Phase Distribution

0

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
4(57.1%)
Phase 3Large-scale testing
1(14.3%)
N/ANon-phased studies
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(2)
Terminated(1)
Other(2)

Detailed Status

unknown2
Completed2
Recruiting1
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (57.1%)
Phase 31 (14.3%)
N/A2 (28.6%)

Trials by Status

unknown229%
recruiting114%
completed229%
not_yet_recruiting114%
terminated114%

Recent Activity

1 active trials
Showing 5 of 7
completedphase_3

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

NCT03169881
recruitingnot_applicable

Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.

NCT07002827
terminatedphase_2

Mechanisms of EPO-induced Hypertension

NCT03810911
not_yet_recruitingnot_applicable

National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis

NCT07131280
completedphase_2

Long-term Pre-dialysis Extension in Europe and Asia Pacific

NCT02055482
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03169881Phase 3

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

Completed
NCT07002827Not Applicable

Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.

Recruiting
NCT03810911Phase 2

Mechanisms of EPO-induced Hypertension

Terminated
NCT07131280Not Applicable

National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis

Not Yet Recruiting
NCT02055482Phase 2

Long-term Pre-dialysis Extension in Europe and Asia Pacific

Completed
NCT00234143Phase 2

Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)

Unknown
NCT00443339Phase 2

Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7